R. Scott Huennekens

September 25, 2026

Keybanc Initiates Coverage on NeuroPace (NPCE) with Overweight Rating. Keybanc has started coverage of NeuroPace, giving it an overweight rating and a price target of $18. This follows the recent average analyst target of $20, which sits near the top of the 52‑week range of $9.22 to $19.60. The new rating adds to the company's positive outlook as it trades near its support level of $14.01 with an RSI of 41.9.

October 14, 2026

QuidelOrtho Reports Q2 2026 Results and New IR Lead. QuidelOrtho released its second-quarter 2026 earnings, with reports noting that profit margins have recovered while cash levels remain a point of discussion. The company also announced the appointment of Sanjeev Sharma as Vice President of Investor Relations. These updates provide context for the stock's current position within its 52-week range.

October 10, 2026

Piper Sandler cuts Envista price target to $26, maintains Neutral. Piper Sandler recently lowered its price target for Envista Holdings to $26 while keeping a Neutral stance. This move aligns with the stock's current trading level near its 52-week low of $18.77. The company has also scheduled its third-quarter 2026 earnings call, which will provide updated financial insights.

September 28, 2026

Hyperfine Expands Portable Brain MRI Reach to Gulf Markets. Hyperfine has announced that its portable brain MRI system will now be available in key Gulf Cooperation Council countries, expanding its global footprint. The move follows the company’s recent rollout in other international markets and could increase adoption in the region’s hospitals. BTIG has reiterated a bullish stance, keeping its $2 price target unchanged. These developments highlight growing interest in Hyperfine’s technology.